Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Labeled Hydroxyphenethylguanidines in Heart Failure
NCT02669563Phase 1Completed
- Sponsor
- University of Michigan
- Start
- Dec 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]4F-MHPG and 3-[18F]fluoro-para-hydroxyphenethylguanidine in heart failure (HF) (2 cohorts), sponsored by University of Michigan. Primary endpoint: Composite measures based on radiotracer tissue uptake ratios and rates of metabolism at 12 months. Started Dec 2015; status: completed.
02
Drugs
[18F]4F-MHPG3-[18F]fluoro-para-hydroxyphenethylguanidine
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02669563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669563.